References
- HigginbothamEJConsiderations in glaucoma therapy: fixed combinations versus their component medicationsClin Ophthalmol201041920169043
- SyedMFLoucksEKUpdate and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertensionClin Ophthalmol201151291129621966204
- ChraiSSMakoidMCEriksenSPRobinsonJRDrop size and initial dosing frequency problems of topically applied ophthalmic drugsJ Pharm Sci1974633333384820359
- JaenenNBaudouinCPouliquenPOcular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol20071734134917534814
- PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol20028641842311914211
- NguyenQHMcMenemyMGRealiniTPhase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%J Ocul Pharmacol Ther20132929029723425430
- NordlundJRPasqualeLRRobinALThe cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidineArch Ophthalmol199511377837826297
- Timolol maleate ophthalmic solution [package insert]Fort Worth, TXFalcon Pharmaceuticals Ltd2004
- RougheadEEKalischLMPrattNLManaging glaucoma in those with co-morbidity: not as easy as it seemsOphthalmic Epidemiol201219748222364388